Udg Healthcare PLC Receives Outperform Rating from Davy Research (UDG)
UDG has been the subject of a number of other recent research reports. Analysts at N+1 Singer reiterated a “buy” rating on shares of Udg Healthcare PLC in a research note on Tuesday. They now have a GBX 410 ($7.03) price target on the stock. Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of Udg Healthcare PLC in a research note on Thursday, June 5th. They now have a GBX 400 ($6.86) price target on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Udg Healthcare PLC from GBX 385 ($6.60) to GBX 400 ($6.86) in a research note on Wednesday, May 14th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of GBX 380 ($6.52).
Udg Healthcare PLC (LON:UDG) traded down 1.41% during mid-day trading on Tuesday, hitting GBX 349.50. The stock had a trading volume of 126,060 shares. Udg Healthcare PLC has a 1-year low of GBX 293.30 and a 1-year high of GBX 380.10. The stock’s 50-day moving average is GBX 344.4 and its 200-day moving average is GBX 350.. The company’s market cap is £843.7 million.
UDG Healthcare plc is an international provider of services to healthcare manufacturers and pharmaceutical retailers, with operations in over 20 countries including the United States, the United Kingdom, Ireland, Germany, the Netherlands and Belgium.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.